A promising area of research on novel anti-malarial drugs has been the disruption of the acylation of key proteins during the parasitic life cycle. Inhibition of an enzyme responsible for one type of acylation, N-myristoylation, has been observed to have pleiotropic effects with severe impacts on parasite development, growth, and multiplication. In Plasmodium falciparum, N-myristoyltransferase (NMT) co-translationally catalyzes the transfer of a 14-carbon moiety from myristoyl coenzyme A to a glycine residue at the amino terminus of a wide range of proteins. This acyl chain is important for the localization of NMT-substrates to specific membranes, allowing them to play roles in host-cell invasion, parasite motility, and protein trafficking and degradation. As a result, NMT has been validated as a therapeutic target for diseases such as malaria.
